aTYR PHARMA (ATYR) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $0.17, -5.43% vs the prior close of $0.18.
- Volume 1.80M shares, 0.5x its 50-day average (light).
- New SEC filings: 8-K (Oct 16, 2026).
- No new insider buys or sales reported since the prior session.
ATYR slides 5.4% to $0.17, a 52-week low. Closed at $0.17, -5.43% vs the prior close of $0.18. Day range $0.17–$0.19, opened at $0.19.
ATYR daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — ATYR slides 5.4% to $0.17, a 52-week low
- Closed at $0.17, -5.43% vs the prior close of $0.18. Day range $0.17–$0.19, opened at $0.19.
- Volume was 1.80M shares, 0.5x its 50-day average of 3.92M — lighter than usual.
- Price is -57.1% vs its 50-day average ($0.41) and -72.5% vs its 200-day average ($0.63).
- 52-week range $0.17–$1.11; today's close sits at 0% of that range, 84.3% below the 52-week high.
Oct 15, 2026 — ATYR rises 0.5% to $0.18
- Closed at $0.18, +0.55% vs the prior close of $0.18. Day range $0.18–$0.20, opened at $0.19.
- Volume was 2.22M shares, 0.6x its 50-day average of 3.89M — lighter than usual.
- Price is -55.4% vs its 50-day average ($0.41) and -71.1% vs its 200-day average ($0.64).
- 52-week range $0.18–$1.11; today's close sits at 0% of that range, 83.4% below the 52-week high.
Oct 14, 2026 — ATYR slides 9.0% to $0.18, a 52-week low, 7 down days in a row
- Closed at $0.18, -8.96% vs the prior close of $0.20. Day range $0.18–$0.21, opened at $0.20.
- Volume was 2.57M shares, 0.7x its 50-day average of 3.86M.
- Price is -56.3% vs its 50-day average ($0.42) and -71.4% vs its 200-day average ($0.64).
- 52-week range $0.18–$1.11; today's close sits at 0% of that range, 83.5% below the 52-week high.
- That makes 7 straight losses.
Oct 13, 2026 — ATYR slides 6.5% to $0.20, a 52-week low, 6 down days in a row
- Closed at $0.20, -6.51% vs the prior close of $0.22. Day range $0.20–$0.22, opened at $0.22.
- Volume was 2.64M shares, 0.7x its 50-day average of 3.82M.
- Price is -52.8% vs its 50-day average ($0.43) and -68.7% vs its 200-day average ($0.64).
- 52-week range $0.20–$1.11; today's close sits at 0% of that range, 81.9% below the 52-week high.
- That makes 6 straight losses.
Oct 12, 2026 — ATYR slides 12.6% to $0.22, a 52-week low, 5 down days in a row
- Closed at $0.22, -12.60% vs the prior close of $0.25. Day range $0.22–$0.25, opened at $0.25.
- Volume was 2.03M shares, 0.5x its 50-day average of 3.79M — lighter than usual.
- Price is -50.2% vs its 50-day average ($0.43) and -66.7% vs its 200-day average ($0.64).
- 52-week range $0.22–$1.12; today's close sits at 0% of that range, 80.8% below the 52-week high.
- That makes 5 straight losses.
Oct 9, 2026 — ATYR slides 3.5% to $0.25, a 52-week low, 4 down days in a row
- Closed at $0.25, -3.53% vs the prior close of $0.25. Day range $0.25–$0.26, opened at $0.25.
- Volume was 996.60K shares, 0.3x its 50-day average of 3.78M — lighter than usual.
- Price is -43.7% vs its 50-day average ($0.44) and -62.0% vs its 200-day average ($0.65).
- 52-week range $0.25–$1.12; today's close sits at 0% of that range, 78.0% below the 52-week high.
- That makes 4 straight losses.
Oct 8, 2026 — ATYR slides 8.3% to $0.25, a 52-week low, 3 down days in a row
- Closed at $0.25, -8.27% vs the prior close of $0.28. Day range $0.25–$0.27, opened at $0.27.
- Volume was 2.75M shares, 0.7x its 50-day average of 3.73M.
- Price is -42.3% vs its 50-day average ($0.44) and -60.8% vs its 200-day average ($0.65).
- 52-week range $0.25–$1.12; today's close sits at 1% of that range, 77.2% below the 52-week high.
- That makes 3 straight losses.
Oct 7, 2026 — ATYR dips 1.8% to $0.28, a 52-week low
- Closed at $0.28, -1.77% vs the prior close of $0.28. Day range $0.27–$0.29, opened at $0.28.
- Volume was 1.12M shares, 0.3x its 50-day average of 3.73M — lighter than usual.
- Price is -37.7% vs its 50-day average ($0.45) and -57.4% vs its 200-day average ($0.65).
- 52-week range $0.26–$1.12; today's close sits at 2% of that range, 75.2% below the 52-week high.
Oct 6, 2026 — ATYR dips 2.4% to $0.28, a 52-week low
- Closed at $0.28, -2.41% vs the prior close of $0.29. Day range $0.28–$0.30, opened at $0.29.
- Volume was 1.02M shares, 0.3x its 50-day average of 3.72M — lighter than usual.
- Price is -37.2% vs its 50-day average ($0.45) and -56.8% vs its 200-day average ($0.65).
- 52-week range $0.26–$1.12; today's close sits at 2% of that range, 74.7% below the 52-week high.
Oct 5, 2026 — ATYR rises 1.0% to $0.29
- Closed at $0.29, +1.05% vs the prior close of $0.29. Day range $0.26–$0.29, opened at $0.28.
- Volume was 1.81M shares, 0.5x its 50-day average of 3.70M — lighter than usual.
- Price is -36.3% vs its 50-day average ($0.45) and -55.8% vs its 200-day average ($0.66).
- 52-week range $0.26–$1.12; today's close sits at 3% of that range, 74.1% below the 52-week high.
Oct 2, 2026 — ATYR dips 2.4% to $0.29, a 52-week low, 3 down days in a row
- Closed at $0.29, -2.38% vs the prior close of $0.29. Day range $0.28–$0.30, opened at $0.29.
- Volume was 1.98M shares, 0.5x its 50-day average of 3.69M — lighter than usual.
- Price is -37.4% vs its 50-day average ($0.46) and -56.4% vs its 200-day average ($0.66).
- 52-week range $0.27–$1.12; today's close sits at 2% of that range, 74.4% below the 52-week high.
- That makes 3 straight losses.
ATYR latest news & SEC filings
Every SEC filing by or about ATYR in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Oct 16, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.07 — Reported shareholder vote results.
Oct 7, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Oct 1, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Oct 1, 2026 · Form 3 — New insider holdings
Initial insider ownership statement (Form 3) — a new director, officer or 10% owner disclosed their holdings
Sep 24, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 8.01 — Reported other events the company considers important.
Sep 11, 2026 · Form DEF 14A — Proxy statement
Proxy statement — agenda for the shareholder meeting (board elections, executive pay, votes)
Aug 31, 2026 · Form PRE 14A — Preliminary proxy statement
Preliminary proxy statement
Aug 7, 2026 · Form S-8 — Employee share plan registration
Registration of shares for employee stock plans (S-8)
Aug 7, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Net income: -$10.31M (prior year -$19.53M) (loss narrowed vs Jun 30, 2025)
- Diluted EPS: -$0.11 (prior year -$0.22) (loss narrowed vs Jun 30, 2025)
Aug 7, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Aug 6, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 31, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 1.02 — Ended a material agreement.
Jul 27, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Jul 8, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Things to know before you trade ATYR
- Last results release: Aug 7, 2026 (8-K Item 2.02). Previous ones: May 15, 2026, May 11, 2026, Mar 5, 2026. Based on that rhythm, the next report is likely around Nov 6, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 4.80% (largest 12.6%). That is a volatile stock.
- Liquidity: about 8.74M shares (≈$1.52M) trade per day on average. Thin volume can mean wider bid/ask spreads.
- 52-week position: $0.17 vs a range of $0.17–$1.11 (0% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 12 open-market buys, 12 sales; latest: Paul Schimmel bought 100,000 shares on May 27, 2026.
- Latest filings: 8-K Oct 16, 2026; 8-K Sep 24, 2026; 10-Q Aug 7, 2026.
- Share count: 98.09M shares outstanding (Jul 31, 2026), +0.1% vs a year earlier.
- Listing: Nasdaq · industry: Biological Products, (No Diagnostic Substances).
ATYR market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 0.19 | 0.19 | 0.17 | 0.17 | 1.80M |
| Oct 15, 2026 | 0.19 | 0.20 | 0.18 | 0.18 | 2.22M |
| Oct 14, 2026 | 0.20 | 0.21 | 0.18 | 0.18 | 2.57M |
| Oct 13, 2026 | 0.22 | 0.22 | 0.20 | 0.20 | 2.64M |
| Oct 12, 2026 | 0.25 | 0.25 | 0.22 | 0.22 | 2.03M |
| Oct 9, 2026 | 0.25 | 0.26 | 0.25 | 0.25 | 996.60K |
| Oct 8, 2026 | 0.27 | 0.27 | 0.25 | 0.25 | 2.75M |
| Oct 7, 2026 | 0.28 | 0.29 | 0.27 | 0.28 | 1.12M |
| Oct 6, 2026 | 0.29 | 0.30 | 0.28 | 0.28 | 1.02M |
| Oct 5, 2026 | 0.28 | 0.29 | 0.26 | 0.29 | 1.81M |
| Oct 2, 2026 | 0.29 | 0.30 | 0.28 | 0.29 | 1.98M |
| Oct 1, 2026 | 0.31 | 0.31 | 0.29 | 0.29 | 2.20M |
| Sep 30, 2026 | 0.31 | 0.32 | 0.30 | 0.30 | 1.80M |
| Sep 29, 2026 | 0.29 | 0.32 | 0.27 | 0.31 | 3.85M |
| Sep 28, 2026 | 0.29 | 0.32 | 0.29 | 0.30 | 4.13M |
| Sep 25, 2026 | 0.31 | 0.32 | 0.28 | 0.31 | 8.36M |
| Sep 24, 2026 | 0.40 | 0.41 | 0.32 | 0.34 | 130.12M |
| Sep 23, 2026 | 0.36 | 0.38 | 0.35 | 0.38 | 1.20M |
| Sep 22, 2026 | 0.38 | 0.38 | 0.35 | 0.36 | 1.33M |
| Sep 21, 2026 | 0.38 | 0.38 | 0.37 | 0.37 | 916.50K |
About aTYR PHARMA
aTYR PHARMA (ATYR) is listed on the Nasdaq and classified by the SEC under “Biological Products, (No Diagnostic Substances)”. Its business address is in SAN DIEGO, CA. State of incorporation: DE. Fiscal year ends December 31. SEC CIK 1339970.
ATYR board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Eric Benevich | Director | May 13, 2026 |
| Timothy Coughlin | Director | May 13, 2026 |
| Jane A Gross | Director | May 13, 2026 |
| Svetlana Lucas | Director | May 13, 2026 |
| Paul Schimmel | Director | May 28, 2026 |
| Sanjay Shukla | President and CEO | Feb 4, 2026 |
| Sara Zaknoen | Director | May 13, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Jill Marie Broadfoot | Chief Financial Officer | Feb 4, 2026 |
| Nancy Denyes | General Counsel | Feb 4, 2026 |
| Sanjay Shukla | President and CEO | Feb 4, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| May 27, 2026 | Paul Schimmel | Buy | 100,000 | $0.50 |
| May 27, 2026 | Paul Schimmel | Buy | 100,000 | $0.50 |
| May 27, 2026 | Paul Schimmel | Buy | 100,000 | $0.50 |
| May 27, 2026 | Paul Schimmel | Buy | 100,000 | $0.50 |
| Feb 4, 2026 | Sanjay Shukla | Sale | 3,745 | $0.98 |
| Feb 4, 2026 | Sanjay Shukla | Sale | 3,745 | $0.98 |
| Feb 4, 2026 | Sanjay Shukla | Sale | 3,745 | $0.98 |
| Feb 4, 2026 | Sanjay Shukla | Sale | 3,745 | $0.98 |
| Feb 4, 2026 | Jill Marie Broadfoot | Sale | 1,558 | $0.98 |
| Feb 4, 2026 | Jill Marie Broadfoot | Sale | 1,558 | $0.98 |
| Feb 4, 2026 | Jill Marie Broadfoot | Sale | 1,558 | $0.98 |
| Feb 4, 2026 | Jill Marie Broadfoot | Sale | 1,558 | $0.98 |
| Feb 4, 2026 | Nancy Denyes | Sale | 1,118 | $0.98 |
| Feb 4, 2026 | Nancy Denyes | Sale | 1,118 | $0.98 |
| Feb 4, 2026 | Nancy Denyes | Sale | 1,118 | $0.98 |
ATYR financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $190.00K | $-74.12M | -0.80 | $-61.99M |
| Dec 31, 2024 | $235.00K | $-64.02M | -0.86 | $-69.12M |
| Dec 31, 2023 | $353.00K | $-50.39M | -0.94 | $-33.22M |
| Dec 31, 2022 | $10.39M | $-45.34M | -1.60 | $-41.89M |
| Dec 31, 2021 | $0 | $-33.77M | -1.77 | $-33.08M |
Latest balance sheet: total assets $69.83M, total liabilities $—, cash $16.16M (as of Jun 30, 2026).
ATYR earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 7, 2026 | 8-K Item 2.02 (results) | $0.51 |
| May 15, 2026 | 8-K Item 2.02 (results) | $0.50 |
| May 11, 2026 | 8-K Item 2.02 (results) | $0.95 |
| Mar 5, 2026 | 8-K Item 2.02 (results) | $0.90 |
| Nov 6, 2025 | 8-K Item 2.02 (results) | $0.77 |
| May 7, 2025 | 8-K Item 2.02 (results) | $3.16 |
| Mar 13, 2025 | 8-K Item 2.02 (results) | $3.99 |
| Nov 7, 2024 | 8-K Item 2.02 (results) | $3.10 |
| Aug 13, 2024 | 8-K Item 2.02 (results) | — |
| May 2, 2024 | 8-K Item 2.02 (results) | — |
| Mar 14, 2024 | 8-K Item 2.02 (results) | — |
| Nov 9, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Biological Products, (No Diagnostic Substances)
Moderna (MRNA)Amgen (AMGN)Gilead Sciences (GILD)Twist Bioscience (TWST)Revolution Medicines (RVMD)Argenx Se (ARGX)Kodiak Sciences (KOD)Greenland Mines (GRML)Halozyme Therapeutics (HALO)Biogen (BIIB)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on ATYR
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.